TY  - GEN
AU  - Sanz-Moreno, Adrián
AU  - Palomeras, Sonia
AU  - Pedersen, Kim
AU  - Morancho, Beatriz
AU  - Pascual, Tomas
AU  - Galván, Patricia
AU  - Benítez, Sandra
AU  - Gomez-Miragaya, Jorge
AU  - Ciscar, Marina
AU  - Jimenez, Maria
AU  - Pernas, Sonia
AU  - Petit, Anna
AU  - Soler-Monsó, María Teresa
AU  - Viñas, Gemma
AU  - Alsaleem, Mansour
AU  - Rakha, Emad A
AU  - Green, Andrew R
AU  - Santamaria, Patricia G
AU  - Mulder, Celine
AU  - Lemeer, Simone
AU  - Arribas, Joaquin
AU  - Prat, Aleix
AU  - Puig, Teresa
AU  - Gonzalez-Suarez, Eva
AU  - Sanz-Moreno, Adrián
AU  - Palomeras, Sonia
AU  - Pedersen, Kim
AU  - Morancho, Beatriz
AU  - Pascual, Tomas
AU  - Galván, Patricia
AU  - Benítez, Sandra
AU  - Gomez-Miragaya, Jorge
AU  - Ciscar, Marina
AU  - Jimenez, Maria
AU  - Pernas, Sonia
AU  - Petit, Anna
AU  - Soler-Monsó, María Teresa
AU  - Viñas, Gemma
AU  - Alsaleem, Mansour
AU  - Rakha, Emad A
AU  - Green, Andrew R
AU  - Santamaria, Patricia G
AU  - Mulder, Celine
AU  - Lemeer, Simone
AU  - Arribas, Joaquin
AU  - Prat, Aleix
AU  - Puig, Teresa
AU  - Gonzalez-Suarez, Eva
PY  - 2021
UR  - https://hdl.handle.net/20.500.12105/25176
AB  - Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was...
AB  - RANK and RANKL protein expression was assessed in samples from HER2-positive breast cancer patients resistant to anti-HER2 therapy and treatment-naive patients. RANK and RANKL gene expression was analyzed in paired samples from patients treated with...
AB  - RANK and RANKL proteins are more frequently detected in HER2-positive tumors that have acquired resistance to anti-HER2 therapies than in treatment-naive ones. RANK (but not RANKL) gene expression increased after dual anti-HER2 neoadjuvant therapy in...
AB  - Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-κB activation. Whether HER2-positive...
LA  - eng
PB  - BMC
KW  - Breast cancer
KW  - HER2
KW  - Lapatinib
KW  - NF-κB
KW  - RANK
KW  - RANKL
KW  - Resistance
KW  - Trastuzumab
TI  - RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
TY  - research article
ER  -